Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
Refine your Search
|
Title
|
Publication Date
|
Price
|
Relevance
|
Infinity Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
100% |
Kyowa Hakko Kirin Co., Ltd. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
97% |
CSL Limited – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
97% |
VasGene Therapeutics, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
93% |
|
Biotechnology
|
Sep 2008 |
£915 |
91% |
Biota Holdings Limited – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
89% |
Panacea Pharmaceuticals, Inc. - Product Pipeline Review
Q1 2011
|
Apr 2011 |
£315 |
80% |
Sun Pharmaceutical Industries Limited – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
80% |
Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
4th edition
|
Oct 2010 |
£1,705 |
78% |
Evotec Aktiengesellschaft – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
78% |
SBI Biotech Co., Ltd. - Product Pipeline Review
Q1 2011
|
May 2011 |
£315 |
77% |
National Institutes of Health (NIH) - Developmental Therapeutics Review
Q4 2010
|
Dec 2010 |
£315 |
75% |
|
Biotech 2010
|
Jan 2006 |
£2,760 |
72% |
|
Veterinary Vaccines
|
Feb 2011 |
£2,845 |
72% |
Prospects for Pharma Mergers, Acquisitions and Alliances
2010-2020
|
Jul 2010 |
£1,499 |
66% |
